Welcome to our dedicated page for Telix Pharmaceut SEC filings (Ticker: TLPPF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Telix Pharmaceuticals Limited (TLPPF) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory submissions, with AI-powered tools to help interpret them. Telix Pharmaceuticals Limited is a foreign private issuer that furnishes current reports on Form 6-K and indicates that it files annual reports on Form 20-F. These filings connect U.S. investors to announcements first made to the Australian Securities Exchange.
Each Form 6-K cover page identifies an attached announcement or press release, typically labeled as Exhibit 99.1. Examples include “Telix JP Morgan Healthcare Conference 2026 Presentation,” “Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions,” “ProstACT Global Study Status,” “1st Patient Dosed in ProstACT Global Randomized Tx Expansion,” “Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded,” and “CMS Grants Transitional Pass-Through Status for Gozellix.” The detailed content is contained in the exhibits, while the Form 6-K itself confirms the nature and title of each disclosure.
On this page, you can review Telix’s Form 6-K submissions as they appear in the SEC’s EDGAR system, with real-time updates as new filings are furnished. AI-generated summaries highlight the key points of lengthy documents, helping you quickly understand the focus of each announcement. You can also use this page to locate Telix Pharmaceuticals Limited’s annual Form 20-F filings when available, giving you a structured way to examine both periodic and event-driven disclosures associated with the TLPPF symbol.
Telix Pharmaceuticals Limited submitted a foreign issuer report to the U.S. securities regulator to furnish investors with a copy of a presentation given at the JP Morgan Healthcare Conference 2026. The company states that it filed an announcement with the Australian Securities Exchange on January 12, 2026 titled “Telix JP Morgan Healthcare Conference 2026 Presentation,” and has attached this as an exhibit for U.S. investors. This filing is primarily administrative, making the same information available in the U.S. market that was released in Australia.
Telix Pharmaceuticals Limited submitted a Form 6-K to share with U.S. investors an announcement it filed with the Australian Securities Exchange. The attached announcement, titled “Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions,” outlines developments in Telix’s precision medicine portfolio. This report mainly serves to furnish that ASX announcement as Exhibit 99.1 for the U.S. market.
Telix Pharmaceuticals Limited submitted a Form 6-K to update U.S. investors on a clinical development milestone first disclosed in Australia. On December 8, 2025, the company filed an announcement with the Australian Securities Exchange titled “1st Patient Dosed in ProstACT Global Randomized Tx Expansion,” and this announcement is attached to the Form 6-K as Exhibit 99.1. The filing itself mainly serves as a cross-border notice and does not include additional financial results or transaction details beyond referencing the attached announcement.
Telix Pharmaceuticals Limited furnished a Form 6-K noting it filed an ASX announcement titled “Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded.”
The exhibit (99.1) highlights reported revenue of US$206 million and an upgrade to FY 2025 guidance, as described in the announcement title. Further operational or financial details are contained in the attached exhibit.
Telix Pharmaceuticals Limited reported that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through status for Gozellix. The company filed an announcement with the Australian Securities Exchange titled "CMS Grants Transitional Pass-Through Status for Gozellix," and the related press release is attached as Exhibit 99.1 to the report. No financial metrics, guidance, or additional transaction details are included in the filing.